The Role of Mitochondrial Bioenergetics in Resilience in Older Adults with Gynecologic Cancer Receiving Cancer Reductive Treatment

Inclusion Criteria

• * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 50 years at the time of enrollment * Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype * Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy * Ability to read and understand the English language

Exclusion Criteria

• * Previously treated for ovarian or endometrial cancer * History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia * Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator * Documented physical or psychological comorbidity that would limit participant’s ability to understand or comply with study procedures for the entire length of the study